目的 探讨注射用环磷腺苷葡胺联合盐酸莫雷西嗪片治疗室性心律失常的临床疗效。方法 选取2016年4月-2017年4月在海南省人民医院治疗的室性心律失常患者202例，根据用药的差别分为对照组（101例）和治疗组（101例）。对照组口服盐酸莫雷西嗪片，150 mg/次，3次/d；治疗组在对照组基础上静脉滴注注射用环磷腺苷葡胺，120 mg加入5%葡萄糖注射液250 mL，1次/d。两组患者连续治疗2周。观察两组患者临床疗效，同时比较治疗前后两组患者心率变异性指标和血清学指标。结果 治疗后，对照组临床有效率为85.15%，显著低于治疗组的97.03%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者全程每5分钟NN节段的窦性RR间期标准差（SDANN）、全程连续窦性RR间期标准差（SDNN）、全程相邻RR之差的均方根（RMSSD）值均显著增加（P<0.05），且治疗组患者SDANN、SDNN、RMSSD值明显大于对照组（P<0.05）。治疗后，两组患者血清超敏C反应蛋白（hs-CRP）、肿瘤坏死因素-α（TFN-α）、白细胞介素-6（IL-6）、B型利钠肽（BNP）水平均显著降低（P<0.05），且治疗组患者这些血清学指标水平明显低于对照组（P<0.05）。结论 注射用环磷腺苷葡胺联合盐酸莫雷西嗪片治疗室性心律失常的疗效显著，可有效改善心率变异性，降低机体炎症反应。

Objective To investigate the clinical efficacy of meglumine adenosine cyclophosphate combined with moricizine in treatment of ventricular arrhythmia. Methods Patients (202 cases) with ventricular arrhythmia in Hainan General Hospital from April 2016 to April 2017 were divided into control (62 cases) and treatment (62 cases) groups based on different treatments. Patients in the control group were po administered with Moracizine Hydrochloride Tablets, 150 mg/time, three times daily. Patients in the treatment group were iv administered with Meglumine Adenosine Cyclophosphate for injection on the basis of the control group, 120 mg added into 5% glucose injection 250 mL, once daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the heart rate variability indicators and serological indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 85.15%, which was significantly lower than 97.03% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the value of SDANN, SDNN, and RMSSD in two groups was significantly increased (P<0.05), and which in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the serum hs-CRP, TNF-α, BNP, and IL-6 levels in two groups were significantly decreased (P<0.05), and these serological indexes in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Meglumine adenosine cyclophosphate combined with moricizine has significant effect in treatment of ventricular arrhythmia, can effectively improve heart rate variability and reduce inflammation.

R972

国家自然科学基金资助项目（81760054）